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1. Introduction
Cytomegalovirus (CMV) is a widespread pathogen that infects a majority of the world’s
population by early adulthood with approximately 50-85% of individuals over 40 being
seropositive [1,2]. CMV can establish a life-long infection with its host by becoming latent
during the lysogenic stage of the viral life cycle in which the virus becomes dormant and the
shedding and production of infectious virions ceases [3]. However, the virus can later re-enter
the lytic stage of the viral life cycle when presented with certain environmental cues, such as
stress, thereby triggering the production of viral progeny and resulting in an acute infection
of the host. Immunocompetent individuals generally display no symptoms of acute CMV
infection, but CMV can cause morbidity and mortality in those with weakened or not fully
developed immune systems [4]. The clinical manifestations of CMV infections in those with
weakened immune systems, include spiking fever, malaise, leucopenia, encephalitis, pneu‐
monitis, hepatitis, uveitis, retinitis, gastrointestinal disease and graft rejection [5,6]. If primary
infection or reactivation of CMV occurs during pregnancy in women, serious complications
will arise for the fetus or developing embryo. CMV is the leading cause of viral birth defects,
including microcephaly, mental retardation, spastic paralysis, hepatosplenomegaly, anemia,
thrombocytopenia, deafness, and optic nerve atrophy that subsequently leads to blindness [5,
7]. CMV is also responsible for 8% of infectious mononucleosis cases [8].
Although immunocompetent individuals generally display no symptoms of CMV infection,
CMV has been implicated in playing a role in several proliferative and inflammatory diseases
[9]. CMV has been linked with several forms of cancer, such as colon, breast, and prostate.
Previously, CMV was regarded as having an oncomodulatory role in cancers by infecting
tumor cells and modulating their malignant properties. It was hypothesized that tumor cells
provided a genetic environment that allowed CMV to exert its oncomodulatory effects. CMV
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was then identified as a potential therapeutic target in those tumors infected with CMV [10-12].
However, recent evidence supports oncogenic properties of CMV in certain cancers, such those
as in salivary gland [13]. Furthermore, epidemiological and pathological studies suggest a
strong link between CMV and atherosclerosis [9]. A potential mechanism for CMV in the
pathogenesis of atherosclerosis involves the reactivation of virus followed by virus-induced
enhancement of vascular inflammation and damage through smooth cell proliferation, uptake
of low-density lipoproteins, and narrowing of the vessel lumen [1].
Antiviral agents that inhibit CMV viral replication exist, including ganciclovir, valganciclovir
(the prodrug of ganciclovir), foscarnet, and cidofovir [1]. The primary mechanism of action of
ganciclovir/valganciclovir against CMV is through the inhibition of the replication of viral
DNA by ganciclovir-5′-triphosphate, which includes a selective and potent inhibition of the
viral DNA polymerase [14]. Foscarnet, by comparison, interferes with the exchange of
pyrophosphate from deoxynucleoside triphosphate during viral replication by binding to a
site on the CMV DNA polymerase [15]. Similarly, cidofovir inhibits CMV DNA synthesis by
DNA chain termination following incorporation of two consecutive cidofovir molecules at the
3'-end of the DNA chain [16]. Nonetheless, the antiviral agents commonly used to treat CMV
infections suffer from high hematologic, renal, and neutropenia toxicity, low bioavailability
and the development of drug-resistant virus strains [9,17]. Furthermore, there is no effective
vaccine available.
The lack of an effective treatment for CMV infections has increased interest in the identification
of targets for the development of novel CMV antiviral treatments. These include proteins
found within the tegument of CMV virions. These proteins are abundant and play pivotal roles
in the viral life cycle, including immune evasion, viral entry, gene expression, assembly of new
virus particles and egress through an envelopment-deenvelopment-reenvelopment process
[18]. The structure of the CMV tegument, the roles of some major tegument proteins in the
CMV life cycle, and the therapeutic potential of CMV tegument proteins will be reviewed.
2. Cytomegalovirus structure and function of the tegument
CMV is a member of the Betaherpesvirinae sub-family of the Herpesviridae family, (Figure 1).
The  virion  has  an  icosahedral  protein  nucleocapsid  that  contains  the  235-kb  double-
stranded DNA. The capsid is surrounded by a proteinaceous tegument and an outer lipid
envelope [1]. CMV virions gain entry into a host cell via a membrane fusion event involving
the outer membrane of the cell and the glycoproteins located on the lipid envelope of the
virion.  When  the  cell  membrane  and  lipid  envelope  fuse,  the  DNA-containing  protein
nucleocapsid and tegument proteins are released into the host cell. This initiates the lytic
stage of the viral life cycle [19].
The proteins in the tegument are excellent candidates for novel CMV antiviral treatments due
to their abundance and significant roles in all stages of the viral life cycle. The tegument, located
between the outer lipid membrane and the icosahedral protein nucleocapsid is largely
unstructured and amorphous although some structuring is seen with the binding of tegument
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proteins to the protein capsid [20]. The tegument proteins comprise more than half of the total
proteins found within infectious CMV virions [21]. Tegument proteins are phosphorylated
and undergo other posttranslational modifications, but the significance of these modifications
is unknown [19]. A common biochemical sequence to direct proteins into the tegument has
not been identified, and the process of assembling the viral tegument upon viral egress and
disassembly upon viral entry into cells is unclear [22]. Incorporation of proteins in the
tegument is likely facilitated by the phosphorylation of the tegument proteins, their subcellular
localization to the assembly site and their interaction with capsids or the cytoplasmic tails of
envelope proteins [18].
As mentioned, the tegument proteins gain entry into the host cell along with the DNA-
containing protein nucleocapsid upon fusion of the outer membrane of the host cell and the
outer glycoprotein riddled lipid membrane of the CMV virion [19]. Once the tegument proteins
are released into the cytoplasm, they become functionally active and participate in all stages
of the viral life cycle [1].
3. Cytomegalovirus tegument proteins
The CMV tegument proteins play pivotal roles illustrated in Figure 2. The known or inferred
functions of tegument proteins are presented in Table 1, compiled using a functional profiling
of the CMV genome from a global mutational analysis [18,62,63]. Gene expression classifica‐
tions are based on when expression occurs during the viral life cycle (Immediate-Early, Early,
Early-Late, and Late). Finally, the tegument proteins are categorized based on their role in lytic
Figure 1. A cartoon depicting the structure of the HCMV virion. (Image obtained from (http://www.virology.net/
big_virology/bvdnaherpes.html website) courtesy of Dr. Marko Reschke in Marburg, Germany).
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replication. Some proteins are essential for replication, while others are required for efficient
replication (augmentative), or dispensable for lytic replication. The roles of major tegument
proteins are presented in sections 3.1-3.4 in the context of the various stages of the CMV life
cycle, which includes viral entry, viral replication and gene expression, immune evasion of the
host, and assembly and egress of new infectious virions.
Figure 2. Illustration of the CMV life cycle from viral entry to egress of new infectious virions.
3.1. Viral entry
Mechanistically, the CMV virions enter host cells through a membrane fusion event involving
the host cell's outer membrane and the glycoproteins located on the lipid envelope of the CMV
virions [19]. The receptors on the viral envelope connect to complementary receptors on the
cell membrane of the host cell. This initial interaction makes the cell susceptible to further
interactions that allow the membranes to fuse, and the subsequent disassembly and release of
the viral genomic DNA and tegument into the host cell. It is believed that several tegument
proteins mediate delivery of the DNA-containing nucleocapsid to the nuclear pore complex
and the release of the viral DNA into the nucleus [18]. Comparisons with other herpesviruses
suggest that the UL47 and UL48 CMV tegument proteins, along with microtubule motor
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proteins, facilitate the delivery of the CMV nucleocapsids to the nuclear pore complex and the
release of the CMV genome into the nucleus [18,64]. Pp150 may also play a role in viral entry
due to its tight association with the CMV capsids [65].
3.2. Viral replication and gene expression
Once the viral genome enters the nucleus of the host cell, the viral immediate-early genes are
expressed through their activation by the pp71 tegument protein, which initiates the lytic stage
of the viral life cycle and the subsequent replication of the 235-kb double-stranded CMV DNA
genome [46]. It is important to note though that the expression of the immediate-early genes
can be repressed resulting in a latent infection that is characterized by the minimization of viral
gene expression and the inhibition of the assembly and egress of new viral progeny [1,66].
Although pp71 is known to play a pivotal role in the expression of the immediate-early genes
during the lytic stage of the CMV life cycle, the gene products of UL35 and UL69 have been
implicated in gene expression [18]. However, more research is necessary to identify the other
tegument proteins involved in viral gene expression.
3.3. Immune evasion
CMV evades the host cell immune system through the targeting of intrinsic, innate, and
adaptive immune responses by several different tegument proteins, including pp65, pp71, and
IRS1/TRS1. pp65 the major tegument protein involved in immune evasion of the host as well
as IRS1/TRS1 modulate the innate and adaptive immune responses. pp71 modulates the
intrinsic immune defense through its neutralization of the Daxx-mediated repression of
immediate-early gene expression. Without immune evasion, the lytic stage of the viral life cycle
is inhibited. The roles of pp65 and pp71 in modulating the host cell immune response is further
discussed below in sections 4.1 and 4.3 respectively [18].
3.4. Assembly and egress
After viral DNA replication, the immediate-early gene products, which include several
tegument proteins as seen in Table 1, turn on the expression of viral late genes [1]. The viral
late proteins are mainly structural components that assist in the assembly and egress of newly
formed infectious CMV virions [1]. The primary tegument proteins involved in assembly and
egress are pp150, pp28, and UL97. pp150 directs the movement of the cytoplasmic capsids to
the site for particle formation, while pp28 directs the enclosure of the tegument proteins and
DNA-containing nucleocapsids within an enveloped particle [18,26,52]. UL97 phosphorylates
the tegument proteins through its kinase activity, which may facilitate the incorporation of the
tegument proteins into new infectious virions [18,30]. Once the virions are packaged, they are
shed from the host cell through an exocytosis mechanism which uses the host cell's transport
system to enclose vacuoles containing the newly synthesized infectious virions for release into
the extracellular space.
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Gene
(Protein) Expression
Essential for Lytic
Replication Known or Inferred Function Reference
UL23 Early-Late Dispensable Involved in events immediately after viruspenetration [23]
UL24 Early-Late Dispensable Involved in events immediately after viruspenetration [23]
UL25 Late Dispensable Structural protein [25]
UL26 Early-Late Augmentative Transcriptional activation [24]
UL32 (pp150) Late Essential Virion egress (directs capsid to the site of finalenvelopment) [26]
UL35 Late Augmentative Viral replication and particle formation [27]
UL36 Immediate-Early Dispensable Control of a caspase-independent cell deathpathway [28]
UL38 Immediate-Early Augmentative Control of apoptosis [29]
UL43 Late Dispensable Involved in events immediately after viruspenetration [23]
UL44 Early Essential CMV DNA polymerase processivity/transcriptionfactor [31]
UL45 Late Augmentative Influences virus growth at low multiplicities ofinfection [32]
UL47 Late Augmentative
Release of viral DNA from nucleocapsid
[33]
Disassembling of virus particles
UL48 Late Essential
Deubiquitinating protease
[34]
Release of viral DNA from capsid
UL50 Early Essential Egress of nucleocapsids [35]
UL53 Late Essential Egress of nucleocapsids [36]
UL54 Early Essential CMV DNA polymerase [37]
UL56 Early-Late Dispensable DNA packaging [38]
UL57 Early Essential Single-stranded DNA-binding protein [39]
UL69 Early-Late Augmentative
Nuclear export of unspliced mRNAs
[40]
Arrests cell cycle in G1 phase
UL71 Early-Late Augmentative/Essential Late envelopment [41]
UL72 Late Dispensable Inactive [42]
UL76 Early Augmentative/Essential Modulation of gene expression [43]
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Gene
(Protein) Expression
Essential for Lytic
Replication Known or Inferred Function Reference
UL77 Early Essential DNA packaging/cleavage [44]
UL79 Early-Late Essential Promotes the accumulation of late viral transcripts [45]
UL82 (pp71) Immediate-Early Augmentative Degrades Daxx; facilitates Immediate-Early geneexpression [46]
UL83 (pp65) Early-Late Dispensable
Endogenous kinase activity
[47,58,59]
Associated kinase activity
Evasion of adaptive immunity
Evasion of innate immunity
UL84 Early Essential CMV DNA replication [48]
UL88 Late Dispensable Unknown N/A
UL93 Late Essential Virion packaging [49]
UL94 Late Augmentative/Essential Putative DNA-binding protein [50]
UL96 Early Augmentative/Essential
Preserves the integrity of the nucleocapsid during
translocation from the nucleus to the cytoplasm [51]
UL97 Early-Late Augmentative
Kinase that phosphorylates UL44
[30,60,61]Stimulates DNA replication, assembly, and egress
Cyclin-dependent kinase-like functions
UL99 (pp28) Late Essential Directs the enclosure of enveloped virus particles [52]
UL103 Late Augmentative Regulates virus particle and dense body egress [53]
UL112 Early Augmentative CMV DNA replication [54]
IRS1/TRS1 Early-Late Augmentative/Essential
Inhibits PKR antiviral response
[55]
Virion assembly
US22 Early Dispensable Involved in events immediately after viruspenetration [23]
US23 Early Augmentative Colocalization with pp65 [57]
US24 Early Augmentative Activation of viral gene expression [56]
Table 1. CMV tegument proteins and their known or inferred function.
4. Cytomegalovirus tegument proteins as potential antiviral targets
Since the CMV tegument proteins play pivotal roles in all stages of the lytic stage of the viral
life cycle, they are candidates for novel antiviral treatments. An antiviral agent able to bind to
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a major tegument protein and inhibit its function would prevent CMV from replicating its viral
DNA genome and producing new infectious virions. This would have great therapeutic value.
Examples of how tegument proteins could be targeted therapeutically are presented below
(See Figure 3).
Figure 3. Current and developmental antiviral agents that target acute CMV infection.
4.1. pp65
A good tegument  protein to  target  would be pp65,  since it  is  the most  abundant  tegu‐
ment protein [67]. pp65 is implicated in counteracting both innate and adaptive immune
responses during CMV infections.  It  invokes humoral  and cellular  immunity and is  the
dominant  target  antigen  of  cytotoxic  T  lymphocytes  [67].  In  addition  to  pp65  being
antigenic, it can also be considered a good antiviral target due to its immunomodulatory
role. pp65 prevents immediate-early proteins from being recognized by components of the
immune  system  in  addition  to  inhibiting  the  synthesis  of  the  various  components  in‐
volved in the host cell’s immune response through its associated enzymatic kinase activity
[58,59]. Thus, if you can inhibit the function of pp65, the host cell immune response would
be able to inhibit the CMV viral life cycle.
Recent evidence in support of pp65 as a target for a novel antiviral treatment strategy concerns
its subcellular localization during the lytic stage of the viral life cycle. pp65 migrates to the
nucleoli at the early stages of infection, which suggests a functional relationship between its
localization and the lytic stage of the viral life cycle [68]. However, pp65 begins to migrate to
the cytoplasm 48 hours into the lytic cycle through cyclin-dependent kinase activity and a Crm
1 exporter mediated migration [69,70]. It is likely that pp65 does not migrate independently
to the nucleoli as it remains in the cytoplasm in the absence of other components of CMV [71,
72]. This is significant as the localization patterns of the tegument proteins are correlated with
their function [73]. Furthermore, pp65 has a bipartite nuclear localization signal, which implies
that the nuclear localization signal is in a region that is initially inaccessible to importin proteins
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[74]. Another tegument protein may bind to pp65,, inducing a conformational change that
allows the inaccessible nuclear localization signal to be recognized by nuclear transport
molecules, triggering the characteristic nuclear localization of pp65 and the initiation of the
lytic cycle [71,72]. Importantly pp65 co-localizes with the tegument protein associated with the
CMV US23 gene product [57]. Thus, the US23 gene product could be the other tegument
protein necessary for pp65 to enter the nucleoli (also see section 4.2 UL97). Thus, two mono‐
clonal antibodies could be developed to target antigens present on the surfaces of pp65 and
the US23 gene product, which would prevent them from interacting and inhibit the develop‐
ment of the lytic stage of the CMV life cycle.
Additionally, pp65 can also be used to develop a vaccine to prevent or inhibit CMV infection.
An excellent example of pp65 being utilized to develop a novel vaccine to prevent CMV
infection concerns the two plasmid DNA vaccine, ASP0113. Currently, ASP0113 is in Phase I/
II clinical trials to prevent CMV infection in solid organ transplant recipients at high risk for
CMV infection. The vaccine is comprised of the highly immunogenic pp65 tegument protein
and the gB CMV surface protein, which utilizes the ability of pp65 to induce cell-mediated
response and gB to induce humoral immune system responses in those infected with CMV.
Results show a reduction in the number of CMV episodes and the time to initial viremia [75].
4.2. UL97
The UL97 gene product is also a tegument protein that could be targeted for the development
of a novel antiviral therapeutic. UL97 stimulates DNA replication, assembly, and egress in
addition to being a known kinase homologue [30,76]. UL97's kinase activity makes CMV
susceptible to the current CMV antiviral ganciclovir, a synthetic 2'-deoxy-guanosine analogue.
UL97 phosphorylates this synthetic analog to a deoxyguanosine triphosphate analogue, which
competitively inhibits the incorporation of it by viral DNA polymerase. This competitive
inhibition results in the termination of CMV DNA elongation [77].
Currently, a specific inhibitor of UL97 protein kinase activity, maribavir, inhibits viral
replication and is in clinical trials [78]. Maribavir is a benzimidazole riboside and inhibits CMV
DNA assembly as well as the egress of CMV nucleocapsids from infected host cells [78].
Maribavir was given fast track status by the Food and Drug Administration and is being
investigated in Phase 2 clinical trials using a high dose treatment option for clinically significant
CMV viremia.
The UL97 gene product also shows due to its association with pp65. UL97 and pp65 act directly
to form a complex during viral replication. When UL97 is genetically ablated or pharmaco‐
logically inhibited, pp65 localizes in unusual refractile bodies, which suggests that UL97 is
essential for the successful localization of pp65 to the nucleus of the host cell at the beginning
of the lytic stage of the viral life cycle [79]. Similarly to US23, UL97 may direct pp65 into the
nucleus to initiate the lytic stage of CMV replication [71,72]. Furthermore, a pp65 deletion
mutant exhibits modest resistance to maribavir [80]. pp65 may negatively regulate UL97 by
sequestering kinase that would be available to promote viral replication [81]. The interaction
between pp65 and UL97 could influence pp65-mediated immune evasion, because the
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presentation of viral immediate-early proteins to T cells is blocked when the proteins are
phosphorylated by UL97 kinase [81,82].
4.3. pp71
pp71 is also a major target for CMV antiviral research as it influences the activation of
immediate-early gene expression at the start of the lytic cycle [83]. Mechanistically, pp71
activates viral gene expression through the neutralization of the effects of the cellular Daxx
protein, which is recruited to promoters by DNA-binding transcription factors, resulting in
the repression of viral transcription [84]. pp71 binds to two inherent domains on Daxx and
induces its proteasomal degradation [85]. pp71 is slows the intracellular transport of MHC
class I molecules, which limits the display of CMV antigens on the surface of infected cells to
cytotoxic T lymphocytes [86].
A UL82 gene deletion mutant may serve as a potential novel CMV vaccine candidate as it can
enter cells efficiently and activate the innate immune response through interactions with cell
surface receptors. However viral gene expression is disrupted during infection when cells are
infected at a low multiplicity of the UL82 gene deletion mutant. The expression of the imme‐
diate-early genes that are involved in the host anti-viral response is blocked. One of the genes
whose expression would be blocked is the immediate-early 2 (IE2) gene that can antagonize
the host innate immune response by attenuating the interferon β response and blocking
chemokine expression. If the expression of IE2 is blocked, the number of cytotoxic T lympho‐
cytes and natural killer cells recruited to the infected cell would increase. Furthermore, viral
replication is limited with low multiplicity of infection with the UL82 gene mutant as this
would promote a robust anti-viral immune response. Thus, a novel antiviral treatment could
target pp71 and its ability to control the activation of immediate-early gene expression [87].
4.4. Tegument structural proteins
The structural proteins of CMV with therapeutic potential include pp150, pp65 (above), pp28,
pp38, and the gene products of UL55 and UL75, as they play pivotal roles in the CMV life cycle
and are immunogenic. pp150, the second most abundant tegument protein behind pp65, plays
a role in the assembly and egress of new infectious virus particles. It is necessary to incorporate
nucleocapsids into these new infectious virus particles [21]. It is essential for maintaining the
stability of the cytoplasmic capsids and directing their movement [1,88]. It also plays a role in
the reorganization of the cytoplasmic assembly compartment during virion assembly [88].
pp28 is largely responsible for the cytoplasmic envelopment of tegument proteins and capsids
during assembly and egress [89].
pp38 is a mitogen-activated protein kinase and has a critical function in CMV viral DNA
replication. pp38 kinase activity is significantly increased after CMV infection, and inhibition
of this kinase activity inhibits CMV-induced hyperphosphorylation of pRb and the phosphor‐
ylation of heat shock protein 27. This suggests that pp38 activation is involved in virus-
mediated changes in host cell metabolism throughout the CMV infection [90].
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The gene products of UL55 and UL75 by comparison have been shown to be involved Sp1 and
NF-kappaB activation during the earliest stages of CMV infection via a cellular receptor-viral
ligand interaction. This is based on the observation that the cellular transcription factors Sp1
and NF-kappaB are upregulated shortly after the binding of purified live or UV-inactivated
CMV to the cell surface, which has also been seen in other systems where cellular factors are
induced following a receptor-ligand interaction [91].
All tegument proteins elicit a strong humoral immune response [92]. This is significant, since
the host immunological functions are clearly limit CMV-associated disease [93]. Novel
therapeutics could take advantage of the highly immunogenic nature of the CMV structural
proteins. Potentially, an antibody could be designed that recognizes the CMV antigens
expressed on these proteins and could be exploited to deliver an active drug compound that
can inhibit the lytic replication of the virus. This strategy is used to target certain cancers.
Additionally, a monoclonal antibody could simply be used to help the immune system locate
the CMV immunogenic structural proteins and end the CMV infection.
Additionally, structural phosphoproteins, such as pp65 and pp150, are good candidates for
subunit vaccine development, since they elicit cytotoxic T lymphocyte responses. A CMV
subunit vaccine would contain viral antigens without the CMV DNA genome. It would be less
likely to cause adverse reactions and would be clinically valuable in view of the high hema‐
tologic and renal toxicity and low bioavailability of current antiviral treatments targeting acute
CMV infection [94].
4.5. UL94
Although it is not critical for viral replication unlike the majority of potential CMV targets,
UL94 could also be targeted by a novel antiviral agent. Studies of UL94 stop mutants show
that UL94 plays a role in the secondary envelopment of viral particles. When the UL94 gene
is absent or not functioning, the UL99 (pp28) tegument protein responsible for the cytoplasmic
envelopment of tegument proteins during assembly and egress exhibits aberrant localization
and there is a complete block of secondary envelopment of virions. Thus, UL94 functions late
in the CMV lytic life cycle to direct pp28 to the assembly complex, facilitating the secondary
envelopment of CMV virions [95].
If a molecule is able to target UL94 and inhibit its function, the assembly and egress of virion
progeny will be blocked, since the secondary envelopment of CMV virions will not occur. A
therapeutic targeting UL94 could utilize the interaction between UL94 and the pp28 structural
protein. For example, a new antiviral could focus on the ability of pp28 to elicit a strong
humoral immune response through the release of antibodies targeting the CMV specific
immunoglobulin as mentioned above. Two monoclonal antibodies could also be developed to
target pp28 and UL94 that could inhibit UL94 from directing pp28 to the assembly complex
where new CMV virion progeny undergo secondary envelopment.
Cytomegalovirus Tegument Proteins and the Development of Novel Antiviral Therapeutics
http://dx.doi.org/10.5772/55156
121
4.6. UL56
Currently, all of the licensed drugs used for the systemic treatment of acute CMV infection act
through similar mechanisms as they target the viral DNA polymerase (UL54) [96]. With the
emergence of ganciclovir-resistant strains of CMV, as well as cross-resistance to second-line
agents (foscarnet and cidofovir), there is a need for new drugs [97].
A promising small molecule antiviral candidate, AIC246, is representative of the 3,4 dihydro-
quinazoline nonnucleoside CMV inhibitors [98]. AIC246 acts through a unique mechanism
distinct from that of the CMV DNA polymerase inhibitors. AIC246 blocks viral replication
without inhibiting the synthesis of progeny CMV genomic DNA or viral proteins. Three pieces
of evidence show AIC246 interferes with CMV DNA cleavage/packaging via a distinct
molecular mechanism from other compounds that target the CMV viral terminase [99]. First,
AIC246 does not affect CMV protein expression or CMV DNA replication, excluding the
possibility of AIC246 acting through interfering with viral genome replication [99]. Second,
genetic mapping of AIC246 resistance to the CMV open reading frame of UL56 shows that the
viral terminase complex is involved in the action of AIC246 [99]. Third, a terminase cleavage
assay showed potent inhibition of the formation of properly processed unit-length genomes
[99]. Thus, AIC246 is a promising therapeutic candidate for the treatment of acute CMV
infection through its unique mechanism of action involving the UL56 tegument protein
involved in DNA packaging.
4.7. Antisense oligonucleotides
The expression of viral genes encoding proteins essential for the production of infectious
virions can also be targeted. Fomivirsen, a 21-base phosphorothioate oligodeoxynucleotide
complementary to the messenger RNA (mRNA) of the major immediate-early region proteins
of CMV, can inhibit CMV gene expression through an antisense mechanism. Fomivirsen binds
to the target mRNA transcripts of the immediate-early region 2 (IE2) that encodes several
proteins responsible for the regulation of viral gene expression. This binding inhibits IE2
protein synthesis and the activation of immediate-early gene expression by pp71, which
subsequently inhibits viral replication [100]. Fomivirsen is licensed to treat acute CMV
infection and illustrates that CMV tegument proteins can targeted indirectly.
5. Conclusion
CMV infects most individuals by early adulthood and is associated with morbidity and
mortality, especially in those with poor immune systems. Furthermore, CMV has been
implicated in inflammatory and proliferative diseases, such as cardiovascular disease and
cancer. Antiviral agents able to inhibit the CMV replication cycle and the production of new
infectious virions exist, but suffer from high levels of toxicity and low levels of bioavailability.
CMV resistant and cross-resistant strains develop because all drugs target the viral DNA
polymerase UL54. There is also no vaccine available to prevent acute CMV infection. However,
several components of the CMV virion are promising targets for novel antiviral therapeutics
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that would inhibit the CMV lytic cycle and eradicate the virus from host cells. The most likely
targets within the CMV virion are those proteins found within the tegument, which is a unique
structure found in all members of the Herpesviridae family. Proteins that localize to the
tegument play pivotal roles in all stages of the CMV life cycle. Novel antiviral therapeutics
that target these proteins inhibit the CMV lytic cycle. Furthermore, the highly immunogenic
nature of several tegument proteins makes them excellent candidates for subunit vaccines. In
fact, several novel antiviral therapeutics and CMV vaccines based around the CMV tegument
proteins are under development. Nonetheless, more research needs to be done to fully identify
the function as well as the role in the lytic stage of the CMV life cycle.
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